年销售额（USD）
500,000,000至749,999,999
企业简介
江苏诺泰澳赛诺生物制药股份有限公司成立于2009年，位于国家级连云港经济技术开发区，现有员工1100余人。公司于2021年5月20日在上海证券交易所科创板挂牌上市 (股票简称: 诺泰生物，代码: 688076)。诺泰生物是一家聚焦多肽、寡核苷酸药物及小分子化药的自主研发与定制研发相结合的国家高新技术企业和省级科技型企业。公司致力于通过技术创新，突破药物研发及生产的技术瓶颈，构建从医药高级中间体、原料药到制剂的全产业链，为全球合作伙伴提供绿色、低成本、优质、高效的医药相关产品和技术服务。
主要竞争优势
品牌,国际认证/标准,经验丰富的研发人员,发货速度,生产能力,产品线丰富,合同定制,接受买家的规格要求,接受小额订单,良好的信誉,优质服务
其他竞争优势
CDMO
PEPTIDE API
PEPTIDE CDMO
多肽专家,国内最大的原料生产供应商。
FDA, NMPA cGMP
Sinopep is specialized in the development and the manufacturing via solid phase peptide synthsis and liquid phase peptide synthesis.
From technical aspect, we have expertise technology of peptide products both in LPPS and SPPS field.
We can adopt the LPPS and SPPS strategoes together for manufacturing peptide products. Such as , Liraglutide and semaglutide projects: We synthesize main chain through SPPS strategy; meanwhile, we obtain side chain and segments via LPPS.
From manufacturing aspect, providing CDMO service from research scale(gram-scale batch) to bulk cGMP Active Pharmaceutical Ingredient (API)(kg-scale batch-10kg-scale batch) . The manufacturing capability of Sinopep is biggest in China at this time.
From regulatory aspect, Sinopep has a strong regulatory background and we are well prepared to fully support you required regulatory documentation such as DMF and technical package. Eptifibatide and bivalirudin DP from our end users are commercialized in EU and US market. Thymalfasin and Octreotide are commercial in China market.
